Education
About Us
Working with TipRanks
Follow Us
Neuren Pharmaceuticals Limited (NURPF)
OTHER OTC:NURPF
Total Valuation
Neuren Pharmaceuticals Limited has a market cap or net worth of $1.04B. The enterprise value is $1.49B.
Market Cap$1.04B
Enterprise Value$1.49B
Share Statistics
Neuren Pharmaceuticals Limited has 126,639,530 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding126,639,530
Owned by Insiders2.40%
Owned by Institutions<0.01%
Financial Efficiency
Neuren Pharmaceuticals Limited’s return on equity (ROE) is 0.09 and return on invested capital (ROIC) is 5.09%.
Return on Equity (ROE)0.09
Return on Assets (ROA)0.09
Return on Invested Capital (ROIC)5.09%
Return on Capital Employed (ROCE)0.07
Revenue Per Employee8.08M
Profits Per Employee3.80M
Employee Count8
Asset Turnover0.19
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Neuren Pharmaceuticals Limited is 78.4. Neuren Pharmaceuticals Limited’s PEG ratio is -1.00.
PE Ratio78.4
PS Ratio36.92
PB Ratio7.05
Price to Fair Value7.05
Price to FCF19.03
Price to Operating Cash Flow11.87
PEG Ratio-1.00
Income Statement
In the last 12 months, Neuren Pharmaceuticals Limited had revenue of 64.63M and earned 30.44M in profits. Earnings per share was 0.24.
Revenue64.63M
Gross Profit64.61M
Operating Income22.02M
Pretax Income38.93M
Net Income30.44M
EBITDA22.05M
Earnings Per Share (EPS)0.24
Cash Flow
In the last 12 months, operating cash flow was 125.42M and capital expenditures -37.00K, giving a free cash flow of 125.39M billion.
Operating Cash Flow125.42M
Free Cash Flow125.39M
Free Cash Flow per Share0.99
Dividends & Yields
Neuren Pharmaceuticals Limited pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.33
52-Week Price Change9.86%
50-Day Moving Average10.89
200-Day Moving Average11.40
Relative Strength Index (RSI)18.72
Average Volume (3m)183.00
Important Dates
Neuren Pharmaceuticals Limited upcoming earnings date is Aug 25, 2026, TBA (Confirmed).
Last Earnings DateFeb 26, 2026
Next Earnings DateAug 25, 2026
Ex-Dividend Date―
Financial Position
Neuren Pharmaceuticals Limited as a current ratio of 76.60, with Debt / Equity ratio of 0.00%
Current Ratio76.60
Quick Ratio76.60
Debt to Market Cap0.00
Net Debt to EBITDA-0.19
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Neuren Pharmaceuticals Limited has paid 8.49M in taxes.
Income Tax8.49M
Effective Tax Rate0.22
Enterprise Valuation
Neuren Pharmaceuticals Limited EV to EBITDA ratio is 108.06, with an EV/FCF ratio of 19.00.
EV to Sales36.86
EV to EBITDA108.06
EV to Free Cash Flow19.00
EV to Operating Cash Flow18.99
Balance Sheet
Neuren Pharmaceuticals Limited has $296.12M in cash and marketable securities with $0.00 in debt, giving a net cash position of $296.12M billion.
Cash & Marketable Securities$296.12M
Total Debt$0.00
Net Cash$296.12M
Net Cash Per Share$2.34
Tangible Book Value Per Share$2.64
Margins
Gross margin is 76.93%, with operating margin of 34.07%, and net profit margin of 47.09%.
Gross Margin76.93%
Operating Margin34.07%
Pretax Margin60.23%
Net Profit Margin47.09%
EBITDA Margin34.11%
EBIT Margin34.07%
Analyst Forecast
The average price target for Neuren Pharmaceuticals Limited is $17.81, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$17.81
Price Target Upside109.04% Upside
Analyst ConsensusStrong Buy
Analyst Count6
Revenue Growth Forecast―
EPS Growth Forecast―